Wednesday, July 8, 2026

biotech · Acute Myeloid Leukemia · Acute Myelogenous Leukemia in Relapse · APTOF

Aptose Biosciences

Aptose Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker APTOF. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Myelogenous Leukemia in Relapse, C

San Diego, USA HQ
2014 Founded
32 Employees
Public company Type
APTOF · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2014
Employees
32
Programs
8
Drugs
1
Patents
7
Clinical program

CG-806

Phase 1 · small molecule · Acute Myeloid Leukemia

CG-806 for Acute Myeloid Leukemia is a Phase 1 program (small_molecule) at Aptose Biosciences with 1 ClinicalTrials.gov record(s).

← All Aptose Biosciences projects Phase 1 small molecule terminated

Internal code APTO-CG-806-03

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Aptose Biosciences
Phase
Phase 1
Modality
small_molecule
Indication
Acute Myeloid Leukemia
Status
terminated
Trials
1

Clinical trials